Wellington Management Group LLP Purchases Shares of 45,581 Indivior PLC $INDV

Wellington Management Group LLP purchased a new position in Indivior PLC (NASDAQ:INDV) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 45,581 shares of the company’s stock, valued at approximately $1,870,000.

Several other hedge funds have also modified their holdings of INDV. Assenagon Asset Management S.A. acquired a new position in Indivior during the 2nd quarter worth $63,224,000. Oregon Public Employees Retirement Fund acquired a new stake in Indivior in the 4th quarter valued at about $1,026,000. Hennion & Walsh Asset Management Inc. acquired a new stake in Indivior in the 2nd quarter valued at about $14,781,000. Handelsbanken Fonder AB purchased a new position in shares of Indivior in the 2nd quarter valued at about $1,859,000. Finally, Royce & Associates LP boosted its stake in shares of Indivior by 24.9% in the 4th quarter. Royce & Associates LP now owns 307,857 shares of the company’s stock valued at $11,046,000 after buying an additional 61,333 shares during the period. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Zacks Research lowered shares of Indivior from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 29th. Craig Hallum reiterated a “buy” rating and issued a $53.00 price target on shares of Indivior in a research note on Tuesday, August 4th. Weiss Ratings raised shares of Indivior from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, September 4th. Finally, Barclays reduced their price objective on shares of Indivior from $46.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday, August 5th. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Indivior presently has an average rating of “Moderate Buy” and an average target price of $45.17.

Insider Activity at Indivior

In related news, CAO Woodrow D. Anderson purchased 1,500 shares of the business’s stock in a transaction that occurred on Thursday, August 27th. The shares were purchased at an average cost of $35.69 per share, for a total transaction of $53,535.00. Following the purchase, the chief accounting officer directly owned 27,638 shares of the company’s stock, valued at $986,400.22. The trade was a 5.74% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Christian Heidbreder sold 18,586 shares of the business’s stock in a transaction on Friday, July 10th. The shares were sold at an average price of $41.14, for a total transaction of $764,628.04. Following the completion of the sale, the insider directly owned 209,337 shares of the company’s stock, valued at approximately $8,612,124.18. This trade represents a 8.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.74% of the stock is currently owned by insiders.

Indivior Stock Performance

Shares of NASDAQ INDV opened at $34.51 on Friday. Indivior PLC has a fifty-two week low of $22.22 and a fifty-two week high of $42.81. The firm has a market capitalization of $4.07 billion, a PE ratio of 12.37 and a beta of 0.82. The stock’s 50-day simple moving average is $38.29 and its 200-day simple moving average is $36.05.

Indivior (NASDAQ:INDV) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $5.75 earnings per share (EPS) for the quarter. The firm had revenue of $343.00 million during the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%. On average, sell-side analysts forecast that Indivior PLC will post 3.66 earnings per share for the current fiscal year.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.